To address these gaps, a prospective study was conducted to compare the populations of CTCs in GC patients using EpCAM, and the corresponding population using CSV-specific antibody 84-1, a validated universal marker for identifying EMT-CTCs in various tumor types. This evidence concerns the gene EPCAM and neoplasm.